ALK- rearrangement in non-small-cell lung cancer (NSCLC)

Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient

(2017) Qing Tian et al.   EUROPEAN RESPIRATORY JOURNAL

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

(2017) Dong-Wan Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK )- rearranged non-small cell lung cancer

(2017) Ka-Won Noh et al.   JOURNAL OF PATHOLOGY

Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment

(2017) Wenbin Li et al.   Journal of Thoracic Oncology

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

(2017) Alice T Shaw et al.   LANCET ONCOLOGY

Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer

(2017) David Hout et al.   Cancers

Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer

(2016) Johanna S. M. Mattsson et al.   BMC CANCER

Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas

(2016) Esther Conde et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

(2016) Sai-Hong Ignatius Ou et al.   JOURNAL OF CLINICAL ONCOLOGY

Second- and third-generation ALK inhibitors for non-small cell lung cancer

(2016) Jingjing Wu et al.   Journal of Hematology & Oncology

MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC

(2016) Leora Horn et al.   Journal of Thoracic Oncology

Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

(2016) Dong-Wan Kim et al.   LANCET ONCOLOGY

Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays

(2016) Antonio Marchetti et al.   LUNG CANCER

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization

(2016) Siraj M. Ali et al.   ONCOLOGIST

Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer

(2016) Miaomiao Wen et al.   OncoTargets and Therapy

Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas

(2015) Michela Boi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Novel ALK fusion partners in lung cancer

(2015) Aglaya G. Iyevleva et al.   CANCER LETTERS

Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

(2015) A. Drilon et al.   CLINICAL CANCER RESEARCH

Novel ALK inhibitors in clinical use and development

(2015) Chaitanya Iragavarapu et al.   Journal of Hematology & Oncology

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib

(2015) Ling Shan et al.   Journal of Thoracic Oncology

Genomic alterations in lung adenocarcinoma

(2015) Siddhartha Devarakonda et al.   LANCET ONCOLOGY

Refining the treatment of NSCLC according to histological and molecular subtypes

(2015) Anish Thomas et al.   Nature Reviews Clinical Oncology

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data

(2015) Gouji Toyokawa et al.   Oncology Research and Treatment

National Working Group Meeting on ALK diagnostics in lung cancer

(2014) Wendy Cooper et al.   Asia-Pacific Journal of Clinical Oncology

ALK Inhibitors: What Is the Best Way to Treat Patients With ALK+ Non–Small-Cell Lung Cancer?

(2014) Gouji Toyokawa et al.   Clinical Lung Cancer

A Novel Fusion of TPR and ALK in Lung Adenocarcinoma

(2014) Yoon-La Choi et al.   Journal of Thoracic Oncology

HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib

(2014) Douglas D. Fang et al.   Journal of Thoracic Oncology

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances

(2014) Florian Cabillic et al.   Journal of Thoracic Oncology

The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization

(2014) Lien Tembuyser et al.   PLoS One

Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma

(2013) J. Ying et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Detection ofEGFRmutations andEML4-ALKrearrangements in lung adenocarcinomas using archived cytological slides

(2013) Natalia V. Mitiushkina et al.   CANCER CYTOPATHOLOGY

Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?

(2013) Renato Franco et al.   Expert Review of Anticancer Therapy

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology

(2013) Antonio Marchetti et al.   Journal of Thoracic Oncology

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays

(2013) Tianhong Li et al.   Journal of Thoracic Oncology

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted Resequencing RevealsALKFusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four Methods

(2013) Katja Tuononen et al.   Biomed Research International

Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing

(2012) Yeonjoo Jung et al.   GENES CHROMOSOMES & CANCER

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer

(2012) Hiroyuki Yasuda et al.   Journal of Thoracic Oncology

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Treating ALK-positive lung cancer—early successes and future challenges

(2012) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology

(2012) Sai-Hong Ignatius Ou et al.   ONCOLOGIST

KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only

(2012) Yuki Togashi et al.   PLoS One

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

(2012) Erik Thunnissen et al.   VIRCHOWS ARCHIV

ALKoma: A Cancer Subtype with a Shared Target

(2012) Hiroyuki Mano   Cancer Discovery

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

(2011) J. M. Heuckmann et al.   CLINICAL CANCER RESEARCH

Anaplastic lymphoma kinase in human cancer

(2011) Antonella Barreca et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Global Patterns of Cancer Incidence and Mortality Rates and Trends

(2010) A. Jemal et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

(2010) T. Sasaki et al.   CANCER RESEARCH

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

(2010) Yihua Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

(2009) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer

(2009) Leora Horn et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

(2008) U. McDermott et al.   CANCER RESEARCH

Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer

(2008) Y. L. Choi et al.   CANCER RESEARCH

Non-solid oncogenes in solid tumors:EML4-ALKfusion genes in lung cancer

(2008) Hiroyuki Mano   CANCER SCIENCE

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

(2008) Kentaro Inamura et al.   Journal of Thoracic Oncology

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA